Cooler Heads

# High-Level Overview

Cooler Heads is a medical device company, not a technology company, though it operates at the intersection of healthcare innovation and patient access technology. The San Diego-based company develops Amma™, an FDA-cleared portable scalp cooling system designed to help chemotherapy patients preserve their hair during treatment.[2][6] The company addresses a critical quality-of-life issue: hair loss from chemotherapy is so emotionally devastating that approximately 8% of eligible patients refuse treatment altogether.[3]

Cooler Heads serves oncology patients and healthcare providers—specifically infusion centers—by offering a user-friendly alternative to traditional cold caps. The company's mission, founded by cancer survivor Kate Dilligan, centers on reducing the physical and emotional toll of cancer treatment.[2] Beyond the device itself, Cooler Heads has built reimbursement infrastructure and patient access platforms to make scalp cooling a seamless part of cancer care workflows.

# Origin Story

Cooler Heads was founded by Kate Dilligan, a breast cancer survivor, whose personal experience with chemotherapy-induced hair loss motivated the creation of Amma.[3] The company emerged from a recognition that existing scalp cooling solutions were cumbersome and inaccessible—requiring dry ice, frequent cap changes, and immobility during infusion.[3]

The timing of Cooler Heads' growth has been strategically advantageous. In 2024, the American Medical Association introduced new Category I CPT codes for scalp cooling services, scheduled to take effect in January 2026, which significantly enhanced insurance reimbursement prospects.[3] This regulatory shift validated the market opportunity and provided momentum for the company's expansion. In July 2025, Cooler Heads closed an oversubscribed $11 million Series A funding round led by Mutual Capital Partners, with participation from seven additional venture investors.[2]

# Core Differentiators

• Portability and ease of use: Unlike traditional cold caps, Amma is a self-administered, portable system that allows patients to move freely within infusion centers during treatment, eliminating the need for dry ice or repeated cap changes.[3]

• FDA clearance and regulatory validation: Amma is the only FDA-cleared portable scalp cooling system on the market, providing clinical credibility and payer confidence.[2]

• Integrated patient access infrastructure: Cooler Heads partnered with Paxos Health to build custom patient-facing portals, provider-facing tools, and reimbursement navigation systems—recognizing that device innovation alone is insufficient without addressing the broader access ecosystem.[1]

• Reimbursement expertise: The company has built data-driven capabilities to help infusion centers navigate payer negotiations and improve provider adoption, directly addressing a major barrier to scalp cooling adoption.[1]

• Founder-led mission alignment: Leadership by a cancer survivor ensures the product development and company strategy remain grounded in authentic patient needs rather than purely commercial incentives.[2]

# Role in the Broader Healthcare Landscape

Cooler Heads is riding a significant wave of regulatory and market validation. The elevation of scalp cooling from Category III to Category I CPT codes in 2026 represents a formal recognition by the American Medical Association that this therapy is an emerging standard of care.[3] This shift addresses a longstanding gap: scalp cooling has existed for decades but remained inaccessible due to reimbursement barriers and provider friction.

The company's success depends on solving a multi-stakeholder problem. Patients need accessible, dignified solutions; providers need seamless workflow integration; and payers need evidence-based reimbursement justification. By combining hardware innovation with software-enabled access infrastructure, Cooler Heads is positioning scalp cooling as a standard oncology service rather than a niche offering.

The broader context matters: cancer care is increasingly focused on quality-of-life outcomes and patient-centered design. Hair loss prevention directly impacts treatment adherence and psychological well-being—metrics that healthcare systems are increasingly incentivized to optimize. Cooler Heads' timing aligns with this shift toward holistic cancer care.

# Quick Take & Future Outlook

Cooler Heads is well-positioned for accelerated growth through 2026 and beyond. The Series A funding will support manufacturing scale-up and commercial team expansion at a critical inflection point—just as reimbursement codes transition to permanent Category I status.[2] This creates a window where early adoption by infusion centers can establish market leadership before competitors enter.

The company's next frontier involves deepening provider adoption and payer coverage. Success will depend on demonstrating that Amma improves not just patient outcomes but also operational efficiency and financial performance for infusion centers. The partnership with Paxos suggests Cooler Heads understands that distribution and access are as important as the device itself.

Looking ahead, the company may expand beyond scalp cooling into adjacent quality-of-life solutions for cancer patients, leveraging its provider relationships and patient access infrastructure. The founder-led mission and venture backing position Cooler Heads to influence how the oncology community approaches treatment side effects—shifting from acceptance to active mitigation.